Astria Therapeutics, Inc. Research and Development in Process
Astria Therapeutics, Inc. reported Research and Development in Process of $164.62 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-22.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-03-22
- Astria Therapeutics, Inc. research and development in process for the quarter ending 2021-12-31 was $0.00.
- Astria Therapeutics, Inc. research and development in process for the quarter ending 2021-09-30 was $0.00.
- Astria Therapeutics, Inc. research and development in process for the quarter ending 2021-06-30 was $5.00K.
- Astria Therapeutics, Inc. research and development in process for the quarter ending 2021-03-31 was $164.61M.
- Astria Therapeutics, Inc. research and development in process for fiscal 2021 was $164.62M.
| Period end | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $0.00 derived: sum of 2 quarters · filed 2023-03-22 | $5.00K derived: sum of 3 quarters · filed 2023-03-22 | $164.62M 10-K · filed 2023-03-22 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $5.00K derived: sum of 2 quarters · filed 2022-11-10 | $164.62M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $164.62M 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $164.61M 10-Q · filed 2022-05-12 |